BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screening-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screening

Published:2024-11 Issue: Volume:288-289 Page:20-31
ISSN:2210-7762
Container-title:Cancer Genetics
language:en
Short-container-title:Cancer Genetics

Author:

Nayak Rojalin,Mallick Bibekanand^ORCID

Publisher

Elsevier BV

Reference62 articles.

1. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary;Louis;Neuro Oncol,2021

2. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial;Gilbert;J Clin Oncol,2013

3. Current FDA-Approved Therapies for High-Grade Malignant Gliomas;Fisher;Biomedicines,2021

4. Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms;Klingler;Cancer Res,2015

5. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics;Sottoriva;Proc Natl Acad Sci U S A,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP